Parallel Review Shouldn’t Entail Comparative Effectiveness, VCs Say
Executive Summary
Any parallel product review process developed by FDA and CMS should not involve new requirements for comparative effectiveness data, the Medical Innovation and Competitiveness Coalition urges in recent comments to the agencies.
You may also be interested in...
CER Has Been A Part Of CMS Coverage Decisions In Recent Years – Avalere
During the health care reform debate, much concern was expressed that results of comparative effectiveness research from the Patient-Centered Outcomes Research Institute could play a key role in Medicare coverage decisions. But CER has already been considered in making Medicare coverage decisions for years, recent Avalere Health analysis of national coverage determinations issued by CMS points out.
CER Has Been A Part Of CMS Coverage Decisions In Recent Years – Avalere
During the health care reform debate, much concern was expressed that results of comparative effectiveness research from the Patient-Centered Outcomes Research Institute could play a key role in Medicare coverage decisions. But CER has already been considered in making Medicare coverage decisions for years, recent Avalere Health analysis of national coverage determinations issued by CMS points out.
FDA/CMS Parallel Review Not Needed For Biopharma Products – PhRMA And BIO
The two major trade associations representing drug and biological manufacturers are telling FDA and CMS that their proposed parallel review process is neither appropriate nor necessary for biopharma products.